LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND as Trustee EIGHTH SUPPLEMENTAL INDENTURE DATED AS OF JANUARY 30, 2015Indenture • January 30th, 2015 • Laboratory Corp of America Holdings • Services-medical laboratories • New York
EIGHTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of January 30, 2015 between Laboratory Corporation of America Holdings, a Delaware corporation (or its permitted successor) (the “Company”), and U.S. Bank National Association, as Trustee under the Indenture (the “Trustee”).
Laboratory Corporation of America Holdings $500,000,000 2.625% Senior Notes Due 2020 $500,000,000 3.200% Senior Notes Due 2022 $1,000,000,000 3.600% Senior Notes Due 2025 $900,000,000 4.700% Senior Notes Due 2045 Underwriting AgreementUnderwriting Agreement • January 30th, 2015 • Laboratory Corp of America Holdings • Services-medical laboratories • New York
Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Seventh Supplemental Indenture to be dated January 30, 2015, the Eighth Supplemental Indenture to be dated January 30, 2015, the Ninth Supplemental Indenture to be dated January 30, 2015 and the Tenth Supplemental Indenture to be dated January 30, 2015 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms
